GlassScriptPhysician profile
Cara B Ballard
NPI 1457310476
$5,046.59
in general payments reported to CMS, 2019-2025
42 companies · $95.15 in 2025
The $95.15 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $394 · 2021: $1,522 · 2022: $1,290 · 2023: $1,137 · 2024: $264 · 2025: $95.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $785.50 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $691.67 | 2019-2025 | |
| Abbvie INC. | $540.29 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $351.67 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $216.10 | 2020-2023 | Trintellix |
| Glaxosmithkline, LLC. | $202.52 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $187.04 | 2022 | |
| Lilly USA, LLC | $180.51 | 2020-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $166.06 | 2021 | |
| Merck Sharp & Dohme LLC | $164.33 | 2019-2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $125.84 | 2021-2023 | Wegovy, Saxenda |
| Novartis Pharmaceuticals Corporation | $121.20 | 2019-2023 | |
| Antares Pharma, INC. | $108.79 | 2021-2023 | Xyosted, Nocdurna, Tlando |
| Esperion Therapeutics, INC. | $107.71 | 2020-2023 | Nexletol |
| Amarin Pharma, INC. | $99.20 | 2021-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.